# OnCo record idea-bio1-arv7-degrader (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-bio1-arv7-degrader/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-bio1-arv7-degrader" ;
  schema:name "Destroy the truncated androgen receptor that hormone drugs cannot touch"@en ;
  schema:description "In advanced prostate cancer the AR-V7 splice variant of the androgen receptor lacks the ligand-binding domain that enzalutamide and abiraterone act on, and its presence predicts resistance. A degrader or N-terminal binder that removes the whole protein, variants included, would still work; AR-V7 is already measurable in circulating tumour cells."@en ;
  schema:url <https://onco.cc/ideas/idea-bio1-arv7-degrader/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/nrc.2017.36> ;
  onco:related <https://onco.cc/roadmaps/prostate-roadmap/>, <https://onco.cc/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/> ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/arvinas/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-dang-nat-rev-cancer/>, <https://onco.cc/key-papers/paper-androgen-receptor-prostate-endocr-rev-2004/>, <https://onco.cc/key-papers/paper-androgen-receptor-prostate-nat-rev-cancer-2015/>, <https://onco.cc/key-papers/paper-androgen-receptor-prostate-acta-pharmacol-sin-2015/> .